OUR SOLUTION – Our science-based solution is called PACT. It’s unique and innovative. PACT is a platelet function test based on flow cytometry, which is recognized as a reliable tool to measure platelet activation. The test determines the reactivity of individual platelets in response to agonist stimulation.
Reactivity is quantified by determining degranulation, measured as P-selectin expression on the platelet surface, as well as activation of integrin αIIbβ3, determined as binding of fibrinogen to the platelets. PACT uses fluorophore conjugated in-house developed nanobodies to detect these specific platelet activation markers. PACT is a platelet activation test based on flow cytometry, a well-recognized and established platform in clinical diagnostics. It analyses platelet function through standardized flow cytometric assessment of platelet activation markers using nanobodies. Its nanobody-based technology allows for simultaneous assessment of multiple platelet activation pathways and
activation parameters. PACT is an easy-to-use, fast and robust diagnostic test providing results from blood collection to clinical diagnosis in less than 2 hours. Since PACT requires only a minimal amount of blood, it provides a patient friendly means of platelet function testing. Furthermore, PACT is the only diagnostic platelet function test that is not affected by platelet count. The PACT test kit contains platelet-activating reagents, nanobodies, internal calibration standards and buffers, and U-PACT offers training and support to allow fast and efficient implementation in clinical diagnostic laboratories.
PACT test benefits:
- Excellent performance characteristics in samples with low platelet count
- Fast and easy to use
- Requires minimal amounts of blood
- Predict bleeding risk in patients with low platelet counts
Charts & Figures
Flow cytometry based solution
Platelet diagnostics in one drop of blood, independent of platelet count. U-PACT has developed a flow cytometry based solution for this problem. In this PACT test, platelets are activated in a test tube, which will result in a change in phenotype that can be measured.Our test uses just one drop of blood, which is added to our proprietary reagent, that contains agonists to activate platelets as well as the means to detect activation status. The need for such a test is underlined by haematologists.
The used technology
PACT proof of concept
High platelet reactivity protects against bleeding in patients with low platelet count. PACT is not influenced by platelet count.
Single center validation study:
- 21 leukemia patients on chemotherapy
- Platelet count < 30% of normal
- WHO bleeding score